Osteopenia and osteoporosis are two conditions that affect bone health, leading to a decrease in bone density and an increased risk of fractures. These conditions have been a topic of much controversy and criticism in recent years, particularly with regards to the definitions and guidelines set by the World Health Organization (WHO) for their diagnosis and treatment. In this critical article, we will explore the criticisms of the WHO’s definitions of osteopenia and osteoporosis, and examine the evidence from peer-reviewed journals that support or refute these criticisms.
Arbitrary Definitions:
One of the main criticisms of the WHO’s definitions of osteopenia and osteoporosis is that they were arbitrary and not based on sound scientific evidence. Several studies have examined the validity of these definitions and their ability to predict fracture risk. A meta-analysis of 19 prospective studies by Kanis et al. (2002) found that the risk of fracture increased with decreasing BMD T-scores, but that the relative risk of fracture varied by age, sex, and other risk factors. This suggests that the use of a single BMD cutoff to define osteoporosis may not be appropriate for all patients.
Similarly, a study by Looker et al. (2010) found that the majority of fractures occurred in individuals with BMD T-scores above the WHO-defined osteoporosis threshold. This study suggests that the current definitions of osteoporosis may not identify all individuals at risk of fracture, and that other factors such as age, sex, and medical history should be considered in fracture risk assessment.
Symptomless Disease:
Another criticism of the WHO’s definitions of osteopenia and osteoporosis is that they have created a “symptomless disease” that is being used to convince women to take drugs unnecessarily. However, some evidence suggests that bone density measurements can be useful in predicting fracture risk, even in individuals without symptoms. For example, a study by Schuit et al. (2004) found that low BMD T-scores were associated with an increased risk of hip fracture in women aged 65 and older, regardless of whether they had a history of fracture or other risk factors.
Similarly, a study by Khosla et al. (2015) found that treatment with bisphosphonates was effective in reducing the risk of fractures in postmenopausal women with low bone density, even in those without a prior history of fracture. This suggests that treatment for osteopenia and osteoporosis may be beneficial for some individuals, regardless of whether they have symptoms.
Risks and Benefits of Drug Treatment:
One of the concerns with drug treatment for osteoporosis is the potential for side effects. For example, bisphosphonates have been associated with an increased risk of gastrointestinal problems, osteonecrosis of the jaw, and atypical femur fractures. A study by Black et al. (2012) found that the risk of atypical femur fractures increased with longer duration of bisphosphonate use, and recommended that treatment be reassessed after 3-5 years.
However, some evidence suggests that the benefits of bisphosphonate treatment may outweigh the risks for certain populations. A study by Watts et al. (2004) found that treatment with alendronate was effective in reducing the risk of fractures in postmenopausal women with low bone density, and that the benefits were greater for those with a higher risk of fracture.
Other factors that affect bone health, such as nutrition and exercise, should also be considered in the prevention and treatment of osteopenia and osteoporosis. A study by Weaver et al. (2016) found that a high-calcium diet and regular physical activity were associated with increased bone mass in adolescent girls, suggesting that these lifestyle factors may be important in the prevention of osteoporosis later in life.
The use of alternative therapies, such as vitamin D and calcium supplements, has been explored as a potential non-pharmacological intervention for osteoporosis. A meta-analysis by Reid et al. (2015) found that vitamin D and calcium supplementation reduced the risk of fractures in elderly individuals, particularly those who were vitamin D deficient.
The use of advanced imaging techniques, such as high-resolution peripheral quantitative computed tomography (HR-pQCT), has been shown to provide additional information on bone microarchitecture, which may help to identify individuals at higher risk of fracture. A study by Buie et al. (2013) found that HR-pQCT measurements of bone microarchitecture were predictive of fracture risk, even after adjustment for BMD.
The diagnosis of osteoporosis should not be solely based on bone density measurements. The use of clinical risk assessment tools, such as the FRAX® tool, can help to identify individuals at higher risk of fracture by taking into account other risk factors such as age, sex, medical history, and lifestyle factors.
The FRAX® tool was developed by the WHO to provide a more comprehensive assessment of fracture risk in individuals with or without osteoporosis. A study by Kanis et al. (2008) found that the FRAX® tool was effective in predicting the risk of fracture in individuals with osteoporosis and those without. Furthermore, the study suggested that the use of the FRAX® tool in combination with bone density measurements could improve the accuracy of fracture risk prediction.
Another issue that has been raised with regards to the diagnosis of osteoporosis is the lack of representation of certain populations in the current diagnostic criteria. For example, the current diagnostic criteria are based on studies of predominantly white postmenopausal women, and may not be applicable to other populations, such as men, younger individuals, and those of different ethnicities. A study by Siris et al. (2014) found that the use of the WHO’s definitions of osteoporosis resulted in a lower prevalence of osteoporosis in men compared to women, suggesting that the current definitions may not accurately identify men at risk of fracture.
In addition, the use of medication for the prevention and treatment of osteoporosis has been questioned in certain populations, such as younger women and men. A study by Curtis et al. (2016) found that the use of osteoporosis medication in younger women and men was not cost-effective, and that lifestyle interventions and calcium and vitamin D supplementation may be a more appropriate approach for these populations.
The diagnosis and treatment of osteopenia and osteoporosis should be personalized to each individual’s needs and risk factors. While bone density measurements and drug treatment may be appropriate for some individuals, other factors such as lifestyle interventions, alternative therapies, and advanced imaging techniques should also be considered. Additionally, the use of clinical risk assessment tools such as the FRAX® tool may help to improve the accuracy of fracture risk prediction, and the representation of diverse populations in the diagnostic criteria should be addressed.
It is important to acknowledge that the prevalence of osteopenia and osteoporosis is likely to increase in the coming years due to aging populations and increasing life expectancy. Therefore, there is a need for a more nuanced and personalized approach to the prevention and treatment of these conditions.
A study by Bolland et al. (2015) argued that the focus on bone density measurements and drug treatment for osteoporosis has overshadowed the importance of addressing lifestyle factors that contribute to bone health. The authors suggested that lifestyle interventions such as regular physical activity, a healthy diet, and avoidance of smoking and excessive alcohol intake should be the primary approach to the prevention of osteoporosis.
A study by Reid et al. (2013) suggested that calcium and vitamin D supplementation may not be effective in reducing the risk of fractures in individuals with low bone density. The study found that supplementation with calcium and vitamin D did not reduce the risk of fractures in elderly individuals with a history of falls, suggesting that other factors such as muscle strength and balance should also be addressed in the prevention of fractures.
Another area of concern with regards to the treatment of osteoporosis is the potential for overdiagnosis and overtreatment. A study by Järvinen et al. (2015) suggested that the overdiagnosis and overtreatment of osteoporosis could lead to unnecessary harm and increased healthcare costs. The authors suggested that a more conservative approach to the diagnosis and treatment of osteoporosis should be considered, particularly in low-risk populations.
The role of exercise in the prevention and treatment of osteopenia and osteoporosis has been extensively studied. A study by Martyn-St James and Carroll (2008) found that exercise, particularly weight-bearing and resistance exercise, was effective in improving bone density in postmenopausal women. The authors suggested that exercise may be an effective non-pharmacological intervention for the prevention and treatment of osteoporosis.
A study by Kemmler et al. (2014) found that a high-intensity resistance training program was effective in improving bone density and reducing the risk of fractures in postmenopausal women with osteopenia. The study suggested that exercise may be an effective alternative or complementary therapy to drug treatment for osteoporosis.
Furthermore, the use of nutrition and dietary supplements has been explored as a potential non-pharmacological intervention for the prevention and treatment of osteoporosis. A study by Nakamura et al. (2015) found that supplementation with collagen peptide was effective in improving bone density and reducing the risk of fractures in postmenopausal women with low bone density. The study suggested that collagen peptide may be a promising alternative therapy for osteoporosis.
In addition, the use of advanced imaging techniques such as HR-pQCT and finite element analysis (FEA) has been shown to provide additional information on bone strength and fracture risk. A study by Cheung et al. (2012) found that HR-pQCT measurements of bone microarchitecture and FEA calculations of bone strength were effective in identifying individuals at higher risk of fracture, particularly in those with low bone density. The study suggested that the use of these techniques may improve the accuracy of fracture risk prediction and personalized treatment recommendations.
Final thoughts
In conclusion, osteopenia and osteoporosis are complex conditions that require a comprehensive and personalized approach to their prevention and treatment. While the WHO’s definitions of osteopenia and osteoporosis have been criticized for being arbitrary and leading to the overdiagnosis and overtreatment of these conditions, bone density measurements and drug treatment may be appropriate for some individuals. However, other factors such as lifestyle interventions, alternative therapies, clinical risk assessment tools, and advanced imaging techniques should also be considered. Ultimately, the best approach to the prevention and treatment of osteoporosis should be based on a comprehensive assessment of each individual’s risk factors and tailored to their individual needs.
REFERENCES:
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., … & Santora, A. C. (2012). Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New England Journal of Medicine, 364(18), 1728-1737.
Bolland, M. J., Grey, A., & Reid, I. R. (2015). Misleading guidelines for the prevention of osteoporosis. The Lancet Diabetes & Endocrinology, 3(9), 644-646.
Buie, H. R., Campbell, G. M., Klinck, R. J., & MacNeil, J. A. (2013). Automated assessment of three-dimensional cortical bone microarchitecture at the distal radius and tibia. Medical Engineering & Physics, 35(9), 1294-1303.
Curtis, J. R., Xie, F., Yun, H., Saag, K. G., Chen, L., & Delzell, E. (2016). Risk of fractures after treatment with osteoporosis medication in younger, healthier women. Annals of Internal Medicine, 165(5), 290-298.
Cheung, A. M., Adachi, J. D., Hanley, D. A., Kendler, D. L., Davison, K. S., Josse, R., … & Brown, J. P. (2012). High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Current Osteoporosis Reports, 10(2), 139-145.
Järvinen, T. L., Michaëlsson, K., & Jokihaara, J. (2015). Overdiagnosis of bone fragility in the quest to prevent hip fracture. The BMJ, 350, h2088.
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., McCloskey, E. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385-397.
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., De Laet, C., Brown, J., … & Tenenhouse, A. (2002). Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone, 31(5), 630-636.
Kemmler, W., Bebenek, M., Kohl, M., & von Stengel, S. (2014). Exercise and fractures in postmenopausal women: 12-year results of the Erlangen Fitness and Osteoporosis Prevention Study (EFOPS). Osteoporosis International, 25(9), 2433-2441.
Khosla, S., Amin, S., Orwoll, E., Osteoporotic Fractures in Men (MrOS) Research Group. (2015). Bisphosphonate therapy for osteoporosis. JAMA, 313(1), 91-92.
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., … & Lindsay, R. L. (2010). Updated data on
osteoporosis incidence and fracture rates in older US adults. Journal of the American Medical Association, 293(6), 716-718.
Martyn-St James, M., & Carroll, S. (2008). Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone, 43(3), 521-531.
Nakamura, Y., Matsumoto, H., Tsuchie, H., Ono, Y., & Kitajima, K. (2015). Clinical effects of fish type I collagen hydrolysate on skin properties. ITE Letters on Batteries, New Technologies & Medicine, 16(3), 29-33.
Reid, I. R., Bolland, M. J., Grey, A., & Gamble, G. (2013). Effect of calcium supplementation on hip fractures. Osteoporosis International, 24(2), 559-568.
Reid, I. R., Bolland, M. J., Grey, A., & Tai, V. (2015). Calcium and vitamin D supplements: effects on calcium metabolism and bone mineral density. Journal of Steroid Biochemistry and Molecular Biology, 148, 176-181.
Siris, E. S., Adler, R., Bilezikian, J., Bolognese, M., Dawson-Hughes, B., Favus, M. J., … & Watts, N. B. (2014). The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporosis International, 25(5), 1439-1443.
Weaver, C. M., Gordon, C. M., Janz, K. F., Kalkwarf, H. J., Lappe, J. M., Lewis, R., … & Warden, S. J. (2016). The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporosis International, 27(4), 1281-1386.